Beijing Tri-Prime Gene Pharmaceutical Co, Ltd. (referred to as Tri-Prime Gene, stock code: 837344) is a modern pharmaceutical biotechnology enterprise with a registered capital of 121.81 million RMB. It is mainly engaged in the research, development, production, and sales of pharmaceutical biotechnology products, including gene engineering drugs, gene engineering vaccines, and diagnostic reagents. It also engages in related technical trade and technical consulting services.
Learn Moreeffective invention patents
1992~2024
Through optimization of vectors for the recombinant protein expression sγδTem in Escherichia coli, optimization of fermentation processes, and purification process improvements, we have taken the lead in China to innova... ...
By establishing a high-stability water solution technology platform for recombinant proteins, we have successfully developed water injections, nebulizers, drops, pre-filled syringes, and various dosage forms of interferon... ...
Currently, the long-acting technology of protein drugs mainly relies on polyethylene glycol (PEG) modification and albumin fusion expression, with industrial applications already realized for imported long-acting antagoni... ...
Tri-Prime Gene will design and establish a cellular therapy engineering center integrated into the company's new factory area for intelligent production and R&D base project construction. This platform possesses natural γ... ...